Correction: Rubidium chloride targets Jnk/p38-mediated NF-κB activation to attenuate osteoclastogenesis and facilitate osteoblastogenesis

Authors

Institutions

Publication Details

Journal
Frontiers in Pharmacology
Published
2026-01-08
DOI
https://doi.org/10.3389/fphar.2025.1678247
Primary Topic
Bone Metabolism and Diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Correction: Rubidium chloride targets Jnk/p38-mediated NF-κB activation to attenuate osteoclastogenesis and facilitate osteoblastogenesis

Hailong Wu, Zhengxiao Ouyang, Qianli Huang, Tang Liu et al.
Frontiers in Pharmacology
Bone Metabolism and Diseases
article

Correction: Rubidium chloride targets Jnk/p38-mediated NF-κB activation to attenuate osteoclastogenesis and facilitate osteoblastogenesis

Hailong Wu, Zhengxiao Ouyang, Qianli Huang, Tang Liu, Bin Liu, Yong Liu
article en

Abstract

No abstract available for this paper.
Frontiers in PharmacologyVol. 16
Central South University (CN), Second Xiangya Hospital of Central South University (CN)
Openalex Percentile: Top 94%
Bone Metabolism and Diseases
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Correction: Rubidium chloride targets Jnk/p38-mediated NF-κB activation to attenuate osteoclastogenesis and facilitate osteoblastogenesis — Hailong Wu, Zhengxiao Ouyang, et al. · Frontiers in Pharmacology (2026) | TGRS Research Map | TGRS